Condition
Solid Tumor and Lymphoma
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Not Yet Recruiting1
Unknown1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07333469Phase 1Not Yet RecruitingPrimary
A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma
NCT05606380Phase 1UnknownPrimary
A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma
Showing all 2 trials